Author:
Pili Roberto,Carducci Michael,Brown Peter,Hurwitz Herbert
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference36 articles.
1. National Cancer Institute, National Institutes of Health: Bethesda, MD (2011) Fact Sheet: Angiogenesis Inhibitors. http://www.cancer.gov/cancertopics/factsheet/Therapy/angiogenesis-inhibitors . Accessed 11 April 2013
2. Bhargava P, Robinson MO (2011) Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep 13:103–111
3. Scagliotti G, Govindan R (2010) Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist 15:436–446
4. Underiner TL, Ruggeri B, Gingrich DE (2004) Development of vascular endothelial growth factor receptor kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem 11:731–745
5. Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335–345
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献